Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Animal health products market

The biotin market is divided between agricultural and human use, with —90% of biotin used in the animal health care market and —10% for the human nutritional market. The major producers of biotin are Hoffmann-La Roche, Lon2a, E. Merck-Darmstadt, Rhc ne-Poulenc, Sumitomo Pharmaceutical, E. Sung, and Tanabe Seiyaku (100). Worldwide production of biotin in 1994 was approximately 60 metric tons. The Hst price for pure biotin in 1995 was — 7.00/g whereas, the Hst price for technical feed-grade biotin was — 5.50/g. Biotin is used in various pharmaceutical, food, and special dietary products, including multivitamin preparations in Hquid, tablet, capsule, or powder forms. One of the commercially available products of i7-biotin is Britrit-1, which is a 1% biotin trituration used in food premixes. [Pg.33]

The market for animal health products is estimated to be over 2 billion in the U.S, and nearly as much in Western Europe Antibiotics dominate the animal health market, and feed additives account for about 50% of that market. [Pg.62]

Animal health is a segment of the life sciences industry at the interface of pharmaceuticals and agrochemicals. Global sales were 15 billion in 2005 ( 14.5 billion in 2004, 13.8 billion in 2001, inflation-adjusted). Of the top 10 companies, 9 are business units or spinoffs from pharmaceutical companies (see Table 11.9). The industry is rather concentrated, with the top 10 companies accounting for 75% of total sales. As they do in pharma, US companies dominate in animal health products. Many of the veterinary products in the portfolios had originally been developed for human use or as pesticides. In the pet (respectively companion animal) segment, which comprises cats, dogs, birds, some rodents, reptiles, and horses and represents about 40% of the total market, the association with human health is particularly prominent. [Pg.106]

Both human and animal health products need to be safe, efficacious, and of defined quality. For major markets in the world, both animal and human products need to be manufactured in GMP facilities. For human products, regulatory requirements are set for the areas of toxicity, safety, dosing intervals, therapeutic effect, stability, manufacturing, etc. Veterinary products not only include all of the above but are also required to address tissue residue, handler safety, and environmental assessment, particularly if the product is for food-producing animals. If producing a new antimicrobial agent for food-producing animals, the issue of antimicrobial resistance also needs to be addressed. Details about these special requirements were covered in section Residue of this chapter. [Pg.305]

Merck is a global research-driven phannaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. In addition, the company manufactures specialty chemical and environmental... [Pg.260]

U.S.A., in lactating dairy cattie to increase milk production. EH Lilly and Company, The Upjohn Company, and American Cyanamid Company also have interests in the commercial appHcation of recombinant bovine GH. Recombinant porcine GH [9061-23-8] preparations from several companies, eg. The Upjohn Company, Smith Kline Beecham Animal Health, Pitman-Moore, Inc., Monsanto Company, and American Cyanamid Company, are being evaluated for commercial use. Recombinant human GH for clinical use is marketed under such names as Protropin (Genentech), Umatrope (EH Lilly), Genotropin (Sumitomo), and Somatonorm (Kabi-Vitmm) by a variety of pharmaceutical companies. A listing of additional suppHers is available (2). [Pg.176]

The discovery and production of antibiotics has been of tremendous importance to human and animal health care. Prior to their discovery about half a century ago, many bacterial infections caused debilitating diseases and fatalities were high. The discovery of antibiotics was a major step in the treatment of infectious diseases, especially those caused by bacteria. Today about 50,000 tonnes of antibiotics are produced annually. About a third of this consists of penicillins, whilst tetracyclines make up about a quarter of the market. [Pg.148]

EMEA. EMEA s mission is to contribute to the protection and promotion of public and animal health by providing high-quality evaluation of medicinal products. Its goal is to develop a single European marketing authorization controlling the safety of medicines for humans and animals. [Pg.350]

Relatively few really new and attractive products have been introduced in the animal health market. The recently developed new and expensive human therapeutics do not play a major role in animal health. Prophylactic vaccines against the major endemic diseases are already available and are difficult to improve for a competitive price. Several other interesting vaccine candidates are stuck in the research phase due to unsurpassable difficulties to achieve sufficient efficacy. [Pg.33]

In 1998, the total animal health market was worth just over 15 billion. Nutritionals, i.e. vitamins, amino-acid supplements, enzymes etc. and vaccines account for 6.3 billion worth of sales, so pharmaceutical type products, the subject of this review, comprise about 60% of the whole (Figure 1). [Pg.45]

Moving on to discuss specific market sectors, I thought I would chart the history of the key milestones in the development of animal health natural product drugs. Whilst the intention is that this review should be an objective discussion of important academic and industrial discoveries, as this is very much a personal perspective, it has been difficult not to include a tinge of commercial bias. Therefore, I chose my starting point as 1849. [Pg.46]

Whilst santonin was not primarily an Animal Health drug, it is a natural product with anthelmintic properties and, as we shall see later, today s antiparasitic market is dominated by a single class of natural products. Although since then, plant metabolites have played a commercial role, the major impact has been made by microbial natural products. [Pg.47]

In summary, there are challenges ahead for natural product drug discovery, natural products have played a major role in the Animal Health market predicting the future will be a judgement call for those involved in the industry. [Pg.58]

The centralised system and to a lesser extent the mutual recognition system have made a significant contribution towards a harmonised market in medicinal products. Both systems have provided a high degree of protection for public health and (in relation to veterinary medicines) animal health. There is a strong desire to retain but improve both systems in parallel. [Pg.633]


See other pages where Animal health products market is mentioned: [Pg.183]    [Pg.3984]    [Pg.295]    [Pg.304]    [Pg.307]    [Pg.13]    [Pg.204]    [Pg.34]    [Pg.169]    [Pg.192]    [Pg.89]    [Pg.90]    [Pg.6]    [Pg.107]    [Pg.108]    [Pg.108]    [Pg.138]    [Pg.3]    [Pg.348]    [Pg.232]    [Pg.121]    [Pg.561]    [Pg.249]    [Pg.33]    [Pg.31]    [Pg.1]    [Pg.45]    [Pg.56]    [Pg.3989]    [Pg.25]    [Pg.302]    [Pg.313]    [Pg.185]   
See also in sourсe #XX -- [ Pg.62 ]




SEARCH



Animal health

Animal health market

Animal health products

Animal production

Animals marketing

Marketed product

Product marketing

© 2024 chempedia.info